Biotech Values

[DewDiligence]

Based on MNTA’s share price action today, relatively few investors evidently expected the en banc rehearing to succeed. From a timing standpoint, the outright denial of the en banc rehearing is better than the scenario in which the CACF conducted the rehearing and eventually ruled against MNTA six months later.

Time to update the news flow post in the MNTA ReadMeFirst again.